Recipient Title President, Chief Executive Officer, Jubilant HollisterStier General Partnership, 16751 Trans-Canada Highway Kirkland QC H9H 4J4 CanadaFEI 3001623073Issued May 28, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3001623073.
Violations2
Issue DateMay 28, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
Jubilant HollisterStier General Partnership
Location
Recipient Title President, Chief Executive Officer, Jubilant HollisterStier General Partnership, 16751 Trans-Canada Highway Kirkland QC H9H 4J4 Canada
FEI Number
3001623073
Country
Canada
Issue Date
May 28, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Subject
CGMP/Finished Pharmaceuticals/Adulterated
Jubilant HollisterStier General Partnership FDA Warning Letter, May 28, 2026
Talk to a Specialist